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To be able to perform a comprehensive and rigorous benefit-risk analysis of individual food components, and of foods, a number of fundamental
questions need to be addressed first. These include whether it is feasible to detect all relevant biological effects of foods and individual food
components, how such effects can confidently be categorised into benefits and risks in relation to health and, for that matter, how health can
be quantified. This article examines the last of these issues, focusing upon concepts for the development of new biomarkers of health. Clearly,
there is scope for refinement of classical biomarkers so that they may be used to detect even earlier signs of disease, but this approach defines
health solely as the absence of detectable disease or disease risk. We suggest that the health of a biological system may better be reflected by
its ability to withstand and manage relevant physiological challenges so that homeostasis is maintained. We discuss the potential for expanding
the range of current challenge tests for use in conjunction with functional genomic technologies to develop new types of biomarkers of health.
Risk-benefit: Nutrition: Biomarkers: Nutritional genomics
We all routinely perform our own personal version of benefit-
risk analysis in the process of making day-to-day decisions,
including our dietary choices. Of course, in relation to the
food we select, this process will normally be anything but sys-
tematic with heavy bias arising from many factors, such as
personal likes and dislikes, mood, time pressures, upbringing,
seasons, education and awareness of nutritional and health
issues.
Even the best informed, most health-conscious and motiv-
ated consumer cannot be getting the analysis exactly right
because not all the information relevant to them is available.
And while the concept of rigorous benefit-risk analysis
should underlie the development of dietary recommendations,
expert panels developing such recommendations have to work
within the constraints of the current limited and fragmented
scientific knowledge base. Unexpected biological effects and
interactions (be they beneficial or detrimental) and inter-indi-
vidual differences in nutritional requirements pose a particular
problem in this respect. Development of a system or frame-
work for performing comprehensive and rigorous benefit-risk
analysis for individual food components, whole foods or
diets, and defining a common scale of measurement for com-
paring the risks and the benefits would be enormously advan-
tageous1. Amongst the challenges involved, several key
questions need to be answered. These include:
. How can health be quantified?
. Is it possible to detect all biological effects of a food
component, food or diet?
. Can these effects confidently be categorised into benefits
and risks?
Within this article we will discuss some limitations of cur-
rent approaches and then: (i) present some ways of thinking
about how to define health; (ii) consider the opportunities
for quantifying risks and benefits of dietary (and other
environmental) factors that genomic technologies present;
(iii) propose possible routes forward, including potentially
useful experimental systems and criteria for selecting food
components that will allow validation and further concept
development.
Developing biomarkers of health
To date, most biomarkers have been developed for the purpose
of detecting disease or deviation from the ‘norm’ that may
signal disease development. From a clinical standpoint, the
most useful biomarkers provide a definitive link to a very
specific disease risk or condition. There is much effort going
into the identification of markers that provide the earliest poss-
ible indication of disease. There is undoubtedly scope to refine
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some current biomarkers so that they can be used to provide
indications of more subtle shifts away from a healthy con-
dition. This might be achieved by focusing upon the functional
significance of the variations within the range of data that
would generally be considered ‘normal’; the aim being to
identify successively earlier indicators of any deterioration.
In assessing how nutrition impinges on health, these mar-
kers are useful but they can only indicate ‘health’ as the
absence of disease. Ideally, we should have markers of
optimal health. There are both practical and theoretical con-
siderations that need to be addressed for the development of
such markers. Optimal biomarkers must be analytically
robust, sensitive, quantitative and practical (e.g. non-invasive).
They also should be mechanism-linked so that implications of
changes can be understood. In general, the most useful
markers would be relevant for the whole population while
also being capable of accounting for the effects of parameters
such as age, gender, ethnicity and genotype.
Even with such refinements, individual markers used in
isolation will not be able to measure health reliably. Instead,
integrated multi-component biomarkers are required. Ideally,
these would examine a far broader concept of health than
simply defining acceptable values for each parameter indivi-
dually. Since biological processes impinge upon each other,
analysis of patterns of parameters will be far more informa-
tive. The ‘omic’ technologies that measure large numbers of
parameters in parallel offer significant opportunities in this
respect. However, even with these new approaches, it is a
major challenge to capture the functional status of a biological
system with measurements at a single static point. Dynamic
measures, taken under varying conditions, may provide a
starting point.
To employ ‘omic’ technologies for defining biological par-
ameters that can be used as markers of health, one first needs
to identify healthy subjects to work with, but the most obvious
way to characterise people as healthy is to use validated mar-
kers of health. Overcoming this apparent paradox requires an
alternative way of identifying genuinely healthy individuals.
We propose that an answer may lie in analysing the robustness
of homeostatic control mechanisms, since a key feature of
health is the ability to cope with, and respond adequately to,
stress (Fig. 1). This approach is already used; for example,
cardiac health is assessed by the response to an exercise
challenge and oral glucose tolerance tests are used to assess
glycaemic control. The concept of using measures of the
robustness of the system to cope with a suitable range of mod-
erate challenges (a so-called ‘stress test’) represents a poten-
tially powerful approach for assessing health status, which
could be used instead of, or in conjunction with, biomarkers
designed to detect disease risk. Acute challenge tests can be
used as sensitive indicators to amplify the response to longer
term differences in dietary patterns and lifestyles.
Robustness can be defined as ‘the ability to maintain per-
formance in the face of perturbations or uncertainty’ and bio-
logical systems employ a range of strategies, such as
redundancy, modularity and feedback control, to achieve
this2. Homeostatic robustness can be evaluated by determining
the scale and duration of perturbations elicited in response to a
standard challenge. Inappropriately large and/or prolonged
deviations from baseline, following an applied stress, may
be used as biomarkers of reduction in robustness with
associated adverse health implications (e.g. impaired glucose
tolerance). On the other hand, it may not be safe simply to
assume the reverse: that the smallest observed deviation
from baseline following a standard stress test represents the
healthiest condition.
An alternative approach would be to test the robustness of a
homeostatic system against a series of challenges of increasing
magnitude. This would provide an indication of the system’s
maximum capacity and a high capacity might be a suitable
indicator of health. However, some caution in the interpret-
ation is still required since there are common trade-offs
between enhancing the robustness of a system to deal with
specific perturbations and increasing its fragility to other
perturbations2,3.
The great advantage of applying ‘omic’ approaches in this
situation is that they can be used to identify and categorise
entire biological responses to different challenges applied
during the proposed stress tests and for determining the rate
and completeness of the return to the original pre-challenge
status for multiple parameters. This information, used in con-
junction with available biological knowledge, can be used to
develop increasingly detailed and accurate models that
describe homeostatic regulatory processes. These kinds of
models not only have the potential to provide new insights
into how biological systems function4,5, they also may provide
a means of identifying the earliest possible indications of long-
term disturbances and compensatory processes3. In this regard,
Fig. 1. Schematic representation of a measured response to a challenge test
in systems of varying robustness. The vertical axis in each graph represents
the magnitude of the perturbation in a hypothetical biological parameter
measured following the challenge. The horizontal axis represents time follow-
ing the challenge. In the ‘healthy’ system (A) the challenge provokes only a
moderate perturbation and homeostatic mechanisms rapidly return the sys-
tem to the basal state. Less robust systems may exhibit increased pertur-
bations following the challenge (e.g. B), delayed return to basal values (e.g.
D) or combinations of the two (e.g. H). Use of functional genomic approach
would enable expansion of this approach combining the response profiles of
many parameters using appropriate multivariate analytical procedures. The
ultimate goal would be to identify a set of parameters, measured at a single
time point, which accurately predicts kinetics of the response.
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current intensive work into the processes underlying chronic
diseases is likely to be extremely valuable6–10. This will
identify responses characteristic of early pathological changes
and thereby help to discriminate these from normal homeo-
static processes.
Given the complexity of the human system, it is possible
that optimal health cannot be categorised as a single state.
Each individual may have the potential to exist in one or
more stable healthy states and these may differ from person
to person and shift with life-stage and lifestyle and be different
for men and women. There may be more appropriate ways to
measure health than simply by seeking to define a single aver-
aged normal standard. Individuality can readily be built into
the challenge model by selecting stressors most appropriate
to an individual’s specific life requirements. In the same
way, this approach also provides the scope to account for
the effects of genotype11.
Challenge/stress tests for quantification of health status
A number of standardised biological stress tests already
exist12–16. For the determination of health, and benefit-risk
analysis of dietary components, it is important to develop a
panel of nutrition-relevant stress tests. These tests should
encompass the major aspects of healthy biological function
and, critically for assessment of diet-related benefit-risk,
should involve challenges that are known to impinge upon
cell functions that are clearly sensitive to dietary components.
We propose the following as examples:
. Infection challenge
. Inflammatory challenge
. Cognitive challenge
. Carbohydrate challenge
. Lipid challenge
. Xenobiotic challenge
. Oxidative challenge
. DNA damage challenge
. Tissue damage challenge
. Exercise challenge.
This list is by no means intended to be exhaustive: substan-
tial expert input would be required to develop and validate a
comprehensive panel of tests. In some cases the challenges
and/or most appropriate readouts to test the function of
these systems are immediately obvious. In others cases,
further technical developments are required. Some of these
functions may be tested comparatively readily in human sub-
jects (e.g. carbohydrate and lipid metabolism and response to
exercise) whereas others would be more difficult to apply in
human subjects for obvious ethical reasons. In such cases,
the functions may be tested in tissue culture and animal
models, and alternative approaches would be needed to take
these tests forward for use in human subjects.
Potential for application of genomic tools
The ‘omic’ technologies (i.e. transcriptomics, proteomics and
metabolomics) are having a substantial impact across the spec-
trum of life science research17. These technologies have
potential for the development and validation of novel bio-
markers of health because they provide simultaneous measure-
ments covering a wide range of biological processes. The data
can be used in pattern-based analysis for defining healthy
biomarker profiles and responses18,19. From another perspec-
tive, the data generated allow identification of both predicted
and unexpected effects; an essential component of any
rigorous benefit-risk analysis.
In most cases, moderate nutritional modifications are likely
to elicit comparatively subtle effects that, even so, may have
profound biological effects in the long term. Detecting such
changes is made more difficult by the degree of variation
between human volunteers. However, several lines of evi-
dence suggest that the degree of intra-individual variation in
multiple parameters determined using ‘omic’ methods is sub-
stantially smaller than the inter-individual variation20–24.
Thus, study designs that enable individuals to act as their
own control are most appropriate. Transcriptomics, proteo-
mics and metabolomics have been applied in a comparatively
small number of human nutritional studies to date25–28.
Nevertheless, these studies demonstrate that ‘omic’ methods
are sufficiently sensitive to detect both acute and chronic
effects of nutrition.
Furthermore, integrated analysis of ‘omic’ data, by taking
small but consistent changes over several components of a
pathway into account, increases the power and the sensitivity
of assessment. For example, de Boer and co-workers were
only able to identify fatty acid catabolism as an effect of quer-
cetin exposure when a pathway analysis programme was
used29. Another example is provided by Mootha and col-
leagues, who described a method, termed gene set enrichment
analysis (GSEA), designed to identify sets of functionally
related genes that differ in expression between experimental
groups30. Using this approach, they were able to identify a
specific set of genes involved in oxidative phosphorylation
(the OXPHOS set), which were expressed at lower levels in
muscle of type 2 diabetics than in control subjects. They
then confirmed a similar pattern of down regulation of the
OXPHOS genes in the muscle of individuals with impaired
glucose tolerance. This finding contrasts with gene by gene
analysis of the same dataset, employing standard statistical
methods with appropriate multiple test correction, which
failed to identify any significant differences. The difference
in expression of members of the OXPHOS gene set between
the diabetic and control groups was typically very modest
(approximately 20 %) but strikingly consistent across the set
(94 of 106 genes). Such small differences would be difficult
to detect reliably on a gene by gene basis even by using
methods such as real-time PCR, which are widely held to be
more sensitive and precise than arrays. Thus, currently, it is
possibly only in the context of global gene expression analysis
that such small differences can be detected and interpreted
with confidence.
In addition to offering improved sensitivity, methods such
as GSEA provide at least two other important benefits. First,
they have proven to be far more effective than single-gene
analyses at revealing common biological effects between inde-
pendent studies31,32. Second, by presenting observed differ-
ences in the form of defined biological processes/pathways,
they make interpretation of study results in relation to avail-
able knowledge more straightforward than considering the
possible biological implications of individual genes in the
gene lists typically generated using the more traditional
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methods. For example, Mootha and colleagues were able to
take forward the observation described earlier by identifying
a subset of the OXPHOS genes that are coordinately expressed
in multiple tissues and then providing direct evidence that this
co-regulation is mediated by PPAR-g coactivator 1a30.
Since this original description, GSEA and variations on this
type of analysis have repeatedly proven their power by provid-
ing new insights into the mechanisms underlying a range of
pathological conditions, including prostatic intraepithelial
neoplasia33, myositis and dermomyasitis34, uterine fibroids35,
exposure to high dose statins36, leukaemia and lung
cancer31. Application and improvement of pathway analyses
and GSEA in combination with other statistical methods that
take interactions into account, such as Random forests37,
will further strengthen sensitivity and accuracy.
Beyond application of these methods individually, inte-
gration of all the ‘omic’ technologies represents the most
powerful way forward. In the longer term, such a systems
biology approach is necessary to cope with the full complexity
of human individuals, their diets and the interactions between
the two. However, integrating transcriptomic, proteomic and
metabolomic datasets is challenging, not least because of the
differences in the timescales of responses of RNA, protein
and metabolites38. This is a particularly important issue in
relation to the challenge test concept, where measuring and
interpreting the dynamics of the response is critical. In
human subjects, changes in blood concentrations of many
metabolites can be detected within minutes of ingesting test
meals and these may persist for a number of hours. Alterations
in gene transcription profile are unlikely to occur quite so
quickly but still can be readily detected within 2 h25. Acute
changes in protein expression following food ingestion in
human subjects have not yet been investigated using a proteo-
mic approach. The complex dynamics of RNA, protein and
metabolite interactions is an issue that is only just beginning
to be dealt with in simple model systems39. Nevertheless,
while the methods necessary to realise full integration are
still in development, examples of studies employing more
than one ‘omic’ technology demonstrate that the descriptive
power of the individual methods can be further enhanced,
even using straightforward integration strategies40–42.
While maximising data capture is the obvious way to start,
this is expensive and labour intensive. In the long run, the aim
should be to define subsets of key parameters and profiles that
will enable the complexity of biomarkers of health to be
reduced without compromising their power. It is possible
that the dynamics of a response could be inferred from a
single sample provided the interrelationships between the
key parameters analysed have been defined clearly. The
‘omics’ technologies can provide us with this insight. Low
cost, high throughput analytical platforms can then be devel-
oped to provide accurate quantification of the specific markers
identified43.
It makes sense to test the new concepts outlined earlier by
exploiting established nutritional models. For example, the
oral glucose tolerance test provides a reference on which to
build a systems biology approach. This could be expanded
by systematic analysis of other standardised dietary challenges
(e.g. lipid loading, vitamin supplementation). Similarly, the
best available models of a healthy phenotype could be used
to evaluate challenge tests. For example, long-term energy
restriction, which is well known to slow ageing and increase
maximum lifespan in Drosophila and C. elegans, rats and
mice44, also improves a host of classical biomarkers of CVD
risk and inflammation in human subjects6,45,46. However,
this model may not be appropriate to use in all contexts and
advocacy of energy restriction for people must still be
considered to be ill advised, based on current knowledge47.
For example, energy restriction can lead to reduction in
bone mineral density, muscle size and strength and aerobic
capacity48,49. Exercise overcomes these effects and, therefore,
a combination of energy restriction with exercise may be more
widely applicable. What is now needed is to use well-charac-
terised model challenge tests to develop the appropriate
experimental design and data analysis required to incorporate
the ‘omic’ technologies and validate their use for benefit-risk
analysis.
Foods and food components
It is essential to start with food components that are well-
characterised in terms of their metabolism, the cellular pro-
cesses they influence and links to specific health outcomes.
The availability of comprehensive dose–response data, both
acute and chronic, from human subjects and different model
organisms would be extremely valuable. Ultimately, the com-
plexity of food has to be taken into account. For example, a
more complex food-based test has been developed for analys-
ing response to a combined glucose and lipid challenge50.
Determining the effects of chronic low exposures on health
poses a particular technical and logistical challenge, but one
that it is vital to address in the context of nutrition. One
approach to overcome this would be to test model organisms
with comparatively short lifespans. Alternatively, with other
models experimental durations could be used that are just suf-
ficiently long for a new state of equilibrium to be reached.
Conveniently, the timescale to reach such a new equilibrium
could be determined using genomic technologies. In addition,
diet at one stage of life can impact on health at a later stage. In
particular, early life nutrition is thought to exert profound
effects on metabolic ‘set points’ 51–53. Functional genomic
technologies may be able to identify early biomarkers of
change, for example, in gene methylation54–56.
Looking beyond the current genomic approach, there are a
wide array of technologies and model systems in development
that may aid the establishment of biomarkers of health that can
then be translated into easy applicable tests. These include
imaging and nano sampling, allowing access to tissues that
thus far are not accessible in living individuals57–59. Applied
to human subjects, this will diminish uncertainties arising
from translation from one species to the other. Furthermore,
the availability of these tools, especially when they can be
applied to human subjects, will reduce animal testing.
Conclusions
Development of complex markers, based on the integration of
challenge tests and genomic technologies represents an excit-
ing, if technically challenging, approach for application as
biomarkers of health and in nutritional benefit-risk analysis.
To make routine use practical, such biomarkers of health
ideally should be based around measurements performed on
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accessible substrates (e.g. biofluids, such as plasma and urine,
blood cells and DNA). However, it will be essential that it is
possible to interpret these biomarkers in the context of func-
tion in multiple tissues. Proof of principle will be facilitated
by pragmatic selection of appropriate challenge tests and diet-
ary constituents with well described bioactivities.
To achieve this, research is needed to: (1) identify challenge
tests relevant to diet-related benefit-risk that can be suitably
adapted to incorporate the ‘omic’ technologies; (2) then to
develop the use of ‘omics’ in such new tests, modifying the
challenge test if necessary, so as to identify novel complex
markers that respond appropriately; (3) finally, to validate
the new complex markers with food components that have
at least some well-characterised physiological effects. Only
then will such tests be ready for the complexities of foods.
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